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Abstract
Background: Agitation in Alzheimer’s disease (AD) is common and associated with poor patient life-quality and carer
distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased
morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other
populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically
significant agitation, in patients with moderate-to-severe AD.
Methods and Findings: We recruited 153 participants with AD and clinically significant agitation from care-homes or
hospitals for a double-blind randomised-controlled trial and 149 people started the trial of memantine versus placebo. The
primary outcome was 6 weeks mixed model autoregressive analysis of Cohen-Mansfield Agitation Inventory (CMAI).
Secondary outcomes were: 12 weeks CMAI; 6 and 12 weeks Neuropsychiatric symptoms (NPI), Clinical Global Impression
Change (CGI-C), Standardised Mini Mental State Examination, Severe Impairment Battery. Using a mixed effects model we
found no significant differences in the primary outcome, 6 weeks CMAI, between memantine and placebo (memantine
lower 23.0; 28.3 to 2.2, p = 0.26); or 12 weeks CMAI; or CGI-C or adverse events at 6 or 12 weeks. NPI mean difference
favoured memantine at weeks 6 (26.9; 212.2 to 21.6; p = 0.012) and 12 (29.6; 215.0 to 24.3 p = 0.0005). Memantine was
significantly better than placebo for cognition. The main study limitation is that it still remains to be determined whether
memantine has a role in milder agitation in AD.
Conclusions: Memantine did not improve significant agitation in people with in moderate-to-severe AD. Future studies are
urgently needed to test other pharmacological candidates in this group and memantine for neuropsychiatric symptoms.
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Introduction
The worldwide prevalence of dementia, of which Alzheimer’s
disease (AD) is the most common aetiology, was estimated as
24.3 million in 2005, doubling every 20 years due to increased
longevity; prevalence is projected to reach 81?1 million by 2040.
[1] Worldwide, dementia contributes 4.1% of all disability-
adjusted life years and 11.3% of years lived with disability [2].
Neuropsychiatric symptoms are common in AD, with agitation
specifically affecting nearly 50% of people with AD over a month.
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[3,4] Symptoms persist for over six months in 80% of those with
clinically significant symptoms, predicted by initial severity.
Agitation is associated with poor quality of life for the person
with AD, deteriorating relationships with family and professional
carers, and institutionalisation [5,6].
The evidence for non-pharmacological treatments is predom-
inantly for people with mild-to-moderate symptoms [7,8] and their
use is often impractical in severe agitation, which carries the
greatest distress and risk. Meta-analyses of drug treatments have
confirmed modest benefits from antipsychotics, particularly
risperidone, olanzapine and haloperidol for agitation in AD over
6–12 weeks (although quetiapine was inefficacious) but with
increased cognitive decline, cerebrovascular events, parkinsonism
and death. [9,10] There is no compelling evidence for other
medications, except for a recent trial of pain management for
agitation in dementia which found that it was more efficacious
than treatment as usual. [11–14] There is therefore an urgent need
to find safe and efficacious pharmacological therapies.
Memantine is an N-methyl-D-aspartate (NMDA) antagonist,
with a half-life of .60 hours, licensed for the treatment of
moderate-to-severe AD. Dosage is usually increased by 5 mg
weekly to 20 mg daily in accordance with the product license.
Memantine reduces glutamatergic dysfunction and may decrease
tau phosphorlyation, which are hypothesised to cause agitation in
AD. [15] A recent meta-analysis concluded that memantine
significantly reduced total neuropsychiatric symptoms compared
to placebo. This is difficult to interpret as the data was not from
clinical populations selected for having clinically significant
neuropsychiatric symptoms. [16] A post-hoc analysis of patients
with moderate-to-severe AD from six trials indicated agitation and
psychosis were the main domains which improved. [17] Analysis
of three trials, indicated significant benefit for memantine versus
placebo in the predefined ‘‘core’’ symptoms [18] (agitation,
delusions and hallucinations)used to measure antipsychotics and
memantine response in dementia and also for agitation at 12 and
24/28 weeks. [19] Again these studies were in populations
recruited for the purpose of testing cognition rather than with
high levels of neuropsychiatric symptoms.
Thus, although emerging evidence highlights the potential of
memantine to treat agitation in people with AD, it is based upon
retrospective secondary analysis, in participants not selected for
problematic agitation. Therefore, prospective evaluation is needed
of whether memantine is of benefit in the treatment of clinically
significant agitation.
This study aims to test the efficacy of memantine versus placebo
in reducing clinically significant agitation, measured using the
Cohen-Mansfield Agitation Score $45 (CMAI), [20,21] at
6 weeks after randomisation and secondarily at 12 weeks. We
hypothesised that treatment with memantine would lead to a
clinically significant improvement (defined a priori as six points on
the CMAI) compared to placebo.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
This study was an investigator inititiated study sponsored by
Lundbeck. Lundbeck was the funder and supplied the study drug
and placebo, but had no role in the study design, data collection,
data analysis, study termination, data interpretation, writing or the
report, or the decision to submit for publication.
Participants
Participants were recruited from nursing or residential care
homes and acute psychiatric wards in the United Kingdom, from
September 2007 to January 2010. The last follow up was in July
2010. Homes and wards were those who agreed to the study across
the sites from which we had ethical and local permission. The
study population were people with AD and agitation judged by
their clinical team to require intervention and referred to the trial.
Inclusion criteria were: a diagnosis of probable AD [22], with a
SMMSE score of#19, Hachinski Score#4, [23] being aged$45,
and a history $two weeks of clinically significant agitation
(requiring treatment) with a CMAI score of $45. Exclusion
criteria were: memantine usage in the four weeks before study
commencement; use of a cholinesterase inhibitor for ,3 months;
dose alteration in the two weeks pre-study of any anti-psychotic,
antidepressant, benzodiazepine, hypnotic or lithium; use of
antiparkinsonian medication; hypersensitivity to memantine;
severe renal impairment; epilepsy, history of convulsions or
seizure, or receiving any anti-epileptic treatment; concomitant
usage of NMDA antagonists such as amantadine, ketamine or
dextromethorphan; recent myocardial infarction, uncompensated
congestive heart failure, uncontrolled hypertension; severe, unsta-
ble or poorly controlled medical illness; and any disability
interfering with the participant completing the study as judged
by the recruiting physician.
Medication
Care home staff supervised patients taking medication. Medi-
cation compliance was monitored by discussing with care staff
whether participants were willing to take the medication and pill
counts for individuals by the research staff and compared to
administration records. Adverse events, vital signs, concomitant
medication and compliance were assessed at each visit.
If participants refused medication for .3 consecutive days,
medication was stopped. The full co-operation of the participant
with testing and physical examination was required for the
baseline assessment. If, during the trial, a participant was
uncooperative with procedures, another attempt was made during
the following seven days. If co-operation was not obtained then
information was collected from staff only.
Randomisation and Masking
Participants were randomly assigned with equal probability to
twice daily memantine 10 mg (titrated in 5 mg increments over
four weeks) or placebo. Randomisation used a secure internet
based randomisation service independent of the study team.
Minimisation was adopted to maintain balance on key confound-
ing variables; centre; age group; sex; dementia (moderate,
moderately severe, severe and very severe); and agitation severity
(CMAI score ,50, 51–55, 56–60, 61–65, 66–70, 71–75 and .75).
Since participants, study personnel, clinicians and carers were
blind to allocation, no probabilistic element was introduced into
the minimisation procedure. Blinding was achieved by using
placebo and active drug identical in appearance and taste. During
the study, the randomisation code was broken only after
withdrawal or completed follow-up. There were eight code breaks:
four at the treating clinician’s request after study participation (two
active and two placebo); the other four because ofserious adverse
events (three memantine and one placebo).
Procedures
The trial was conducted in accordance with Good Clinical
Practice guidelines, the Declaration of Helsinki, the Clinical Trials
Memantine for Agitation in Alzheimer’s Disease
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Regulations and local laws and regulations. We obtained written
ethics approval for the study from South East Multi-Centre
Research Ethics Committee-REC reference 06MRE01/82 for the
trial including our procedures to assess capacity to consent and
written and verbal documentation of assent and written docu-
mentation of consent.
Referring clinicians initially approached participants and their
legal representatives with study information, obtaining verbal
agreement to share information with the researchers who then
contacted the care home and the patient’s legal representative
asking for consent to assess for trial eligibility.
We assessed capacity to give informed consent to participate.
Capacity to give consent according to the Mental Capacity Act
2005 was established and documented by a psychiatrist with a
professional qualification in psychiatry. When present, written
consent was obtained from the participant and legal representa-
tives or next-of-kin were consulted. When capacity was lacking,
verbal or written assent was obtained from the participant and
documented. Written agreement was obtained from an appointed
guardian if they existed, if not from next–of-kin and if there was no
next of kin from carers. Participants and their next-of-kin/carers
could withdraw participation at any time.
Physicians assessed trial eligibility, reviewed medical histories,
recent blood tests, and undertook physical examinations at
baseline to exclude agitation caused by co-morbid physical illness.
Full Blood Counts, Liver Function Tests, Urea & Electrolytes,
Thyroid Function Tests, B12, folate, glucose and cholesterol were
measured unless recent (,3 months) blood tests were available
and the clinical situation was unchanged. If new or significant
abnormalities were discovered the clinician liaised with primary
care and requested further investigations.
The CMAI was assessed at baseline and at weeks 2, 4, 6 and 12.
It contains 29 items each scored from 1 –7 with one meaning
‘‘never’’ and seven ‘‘several times per hour’’ and is validated to
measure agitation.
In addition we tested a number of secondary outcomes: the
effect of memantine versus placebo on the CMAI at 12 weeks; at 6
and 12 weeks on Neuropsychiatric Inventory (NPI; [24]), Clinical
Global Impression Change (CGI-C; [25]), Standardised Mini-
Mental State Examination (SMMSE; [26]) and Severe Impair-
ment Battery (SIB; [27]). In addition, we explored a CMAI-based
response as a 50% reduction in score between baseline and
6 weeks. We also compared the number of occasions rescue
treatment was utilised, and adverse effects.
The NPI is a semi-structured instrument carer rated instrument.
All items were rated by the home staff as in the other informant
interviews. The 12 domains cover delusions, hallucinations,
agitation/aggression, depression/dysphoria, anxiety, elation, apa-
thy, disinhibition, irritability/lability, aberrant motor behaviour,
sleep and appetite disturbance. Each item is rated by frequency
(score: 0–4) and severity (score: 0–3) and the product is the overall
score.
SMMSE is a brief widely used test of cognitive function.
SIB is a cognitive scale designed for severe dementia.
CGI-C is a clinician-rated global measure of change.
To maximise trial retention we used a ‘rescue’ protocol during
the titration period only if it was felt that the safety of the
participant or caregiver was compromised. This started with non-
medication approaches, such as staff reassurance and advice on
managing agitation in dementia, using an information sheet and
checklist. Then trazodone was used as rescue medication at a dose
of 50–150 mg. The protocol was derived from an existing study
[14] and best practice defined through consensus discussion within
the study team.
Power Calculation
The sample size was calculated using NCSS PASS and
employed a repeated measures approach because the primary
outcome is measured at baseline and then weeks 2, 4, 6 and 12. A
first order auto covariance structure for the observations was
assumed. We pre-specified a clinically important difference of 6
points on the CMAI [28] at 6 weeks between the memantine and
placebo groups. We estimated a pooled standard deviation (SD) of
16.84 using data from all medication intervention trials using the
CMAI. Test-retest scores for CMAI, indicated a correlation of 0.6
between successive observations for an individual patient during
treatment. [29] With statistical significance level set at 5%, two-
tailed tests and 80% power, we required two study groups each
with 68 participants. Assuming 20% attrition, this inflated the
sample size to 82 per group. During the study, loss to follow-up at
6 weeks was ,20% and the sample size was therefore adjusted to
148 participants.
Statistical Analysis
We generated frequencies and presented mean and SD for
continuous and proportions for categorical results. The program
package R (2.12.2) was used [30].
The primary analysis was an intention to treat (ITT) analysis;
participants were analysed as part of their allocated group
irrespective of medication protocol adherence. Linear mixed
effects (lme) modeling was used to handle the repeated measure-
ments data. The dependent variables were score at weeks 2, 4, 6
and 12. Group and week were factors and baseline score was used
as adjusting covariate. A first order autoregressive model was used
for the correlation structure. Model fit was judged by standard
residual analyses. In addition bootstrap analyses were performed
that confirmed the parametric results.A sensitivity analysis of
observed cases was used for the CMAI. An ‘observed case’ is
defined as a person who remained in the trial until the assessment
date and took medicine according to protocol i.e. did not miss
.3 days. A similar approach was taken in the analysis of
secondary outcomes. Descriptive statistics were used for safety
and tolerability, tabulating adverse events frequency by treatment
group.
Results
Recruitment and flow of participants in the trial is shown in the
consort diagram (figure 1) 153 participants were randomised and
149 started the trial (72 memantine, 77 placebo). Four participants
were excluded before starting the trial due to randomisation error,
death, change in legal status and medical contraindication. Groups
were balanced on demographic and clinical variables (see
table 1).Concomitant stable psychotropic medication was allowed
at baseline (see table 1).
34 (23%) participants who commenced pharmacotherapy
withdrew before week 6; 19 memantine (26%) and 15 placebo
(19%). Overall there was no significant difference in withdrawal
rates between groups (19 memantine, 15 placebo; p = 0.33), or use
of rescue protocol (7 memantine; 13 placebo; p= 0.20). Medica-
tion was prescribed to treat challenging behaviour upon
withdrawal from the trial medication three times (memantine = 1,
placebo= 2).
Primary Outcome and CMAI Results
(table 2 shows baseline scores, the mean scores at week 6 and
12, and the mean effect of memantine versus placebo for primary
and secondary outcomes; figure 2 shows changes in CMAI over
time).
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The mean CMAI score at baseline was 68.3 for both
memantine and for placebo and this reduced in both groups at
week 6 to 52.5 and 55.6, memantine versus placebo. The primary
outcome,analyzed using a mixed effects model with AR1
covariance structure, showed no significant differences between
memantine and placebo at 6 weeks mean difference in memantine
versus placebo score [23.0 (95% CI 28.3 to 2.2)] (p = 0.26).
At week 12, the mean CMAI score was 53.5 and 57.3 for
memantine and placebo respectively; the mean difference
adjusting for baseline was [23.8 (95% CI 29.1 to 1.5)], but was
not statistically significant (p = 0.16). There was no significant
effect of the treatment group, visit or interaction between them for
scores at weeks 2, 4, 6 and 12. Only baseline CMAI significantly
predicted CMAI score at 6 and 12 weeks (p,0.00005). The results
in our observed cases analysis, with 76 participants in the placebo
and 69 in the memantine group at 6 weeks, were similar and non-
significant (p = 0.19). Seven memantine and 4 placebo participants
had a 50% reduction in CMAI score between baseline and
6 weeks; odds ratio after adjustment for baseline CMAI score, was
1.96 (95% CI 0.47 to 9.54).
Figure 1. CONSORT STATEMENT.
doi:10.1371/journal.pone.0035185.g001
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Other Secondary Outcomes
NPI (Figure 3 shows the changes over time in graph form).
At baseline the mean NPI score was 37.1 for memantine and
36.1 for placebo. This decreased in both groups at week 6 (to 19.8
and 26.4 for memantine and placebo respectively). At week 6, the
mean difference in memantine versus placebo score adjusting for
baseline favoured memantine [26.9 (95% CI 212.2 to 21.6) and
was significant (p = 0.012). At week 12 the mean NPI score for
memantine was18.4 and placebo 27.8. The mean difference in
memantine versus placebo score adjusting for baseline favoured
memantine [29.6 (95% CI –15.0to 24.3] and was significant
(p = 0.0005).
We therefore decided to conduct a post-hoc analysis of whether
the differences in scores in a previously defined NPI symptom
cluster (agitation/aggression, delusions and hallucinations)(19)was
significant. We found the mean values on this cluster at week 6
were 4.48 (SD=5.2)for memantine and 6.6 (SD=6.3) for placebo.
The mean difference in memantine versus placebo score when
adjusted for baseline favoured memantine [22.1(95% CI 24.0 to
20.2) and was statistically significant (p = 0.03). The mean values
at week 12 were 5.7 (SD=6.6) for memantine and 6.7(SD=6.5)
for placebo and the mean difference in change adjusted for
baseline [21.3 (95% CI 23.2 to 0.6)], was not statistically
significant (p = 0.17).
Table 1. Baseline demographic and clinical values at randomisation according to study group.
Placebo(N=77) Memantine(N=72)
Demographic Characteristics
Age (years) (SD) 84.4 (6.6) 84.9 (6.7)
Men: women 19:58 20:52
White UK 75 (97.4%) 71 (98.6%)
Staging of dementia (FAST) Moderately severe 24 (31.2%) 25 (34.7%)
Severe 42 (54.5%) 35 (48.6%)
Very severe 11 (14.3%) 12 (16.7%)
Mean Hachinski Ischemia Score (SD) 1.2 (1.15) 1.4 (1.4)
Baseline Clinical Mean/Median Values
CMAI (SD) 68.3 (19.2) 68.3 (16.1)
MMSE (SD) 7.3 (6.4) 7.3 (6.2)
NPI (SD) 36.1 (19.2) 37.1 (17.4)
SIB (SD) 54.1 (33.4) 52.7 (32.7)
Concomitant Psychotropics Cholinesterase Inhibitor 18 14
Antipsychotics 28 30
Antidepressants 48 41
Benzodiazepines/Sleeping tablets (regular or prn) 44 26
doi:10.1371/journal.pone.0035185.t001
Table 2. Baseline, 6 and 12 week means and mean differences of memantine versus placebo using last outcome carried forward














CMAI Memantine 72 68.3 (64.5; 72.6) 52.5 (48.6; 56.5) 23.0 (28.3; 2.2) 53.5 (49.0; 57.9) 23.8 (29.1, 1.5)
CMAI Placebo 77 68.3 (64.0; 72.6) 55.6 (51.4; 59.8) 57.3 (52.8; 61.8)
NPI Memantine 73 37.1 (32.9; 41.3) 19.8 (16.2; 23.3) 26.9 (212.2; 21.6)* 18.4 (15.1; 21.8) 29.6(215.0; 24.3)***
NPI Placebo 65 36.1 (31.7; 40.5) 26.4 (22.4; 30.3) 27.8 (23.2; 32.4)
SIB Memantine 72 52.7 (45.1; 60.3) 53.7 (46.0;61.3) 3.5 (21.4; 8.5) 53.2 (45.7; 60.7) 8.0 (3.1; 13.0)**
SIB Placebo 77 54.1 (46.6; 61.5) 51.3 (43.6; 59.0) 46.4 (38.4; 54.3)
SMMSE Memantine 72 7.3 (5.9; 8.7) 7.9 (6.3; 9.4) 0.98 (20.04; 2.0) 8.2 (6.6; 9.7) 1.4 (0.4; 2.4)**
SMMSE Placebo 77 7.3 (5.9; 8.8) 6.9 (5.4; 8.4) 6.8 (5.4; 8.20
CGI-C Memantine 72 NA 3.3 (2.9, 3.6) 20.2 (20.6; 0.3) 3.1 (2.7; 3.4) 20.3 (20.8; 0.1)
CGI-C Placebo 77 NA 3.4 (3.1, 3.7) 3.4 (3.1; 3.8)
The effect at weeks 6 & 12 uses lme and adjusts for baseline for CMAI, NPI, SIB and SMMSE.* p,0.05 ** p ,0.01 *** P,0.001. NPI = Neuropsychiatric Inventory;
CGIC = Clinical Global Impression of change; SMMSE = Standard Mini Mental State examination; CMAI = Cohen Mansfield Agitation Index; SIB = Severe Impairment
Battery.
doi:10.1371/journal.pone.0035185.t002
Memantine for Agitation in Alzheimer’s Disease
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e35185
CGIC
There was no statistically significant difference in the CGIC
between memantine and placebo groups p= 0.45 at week 6 and
p= 0.11 at week 12.
Cognition
The mean difference in SIB score between memantine and
placebo was significant at week 12 and this favoured memantine
[8.0 (95% CI 3.1 to 13.0; p,0.005], but not week 6 (3.5(95% CI
21.4 to 8.5; p= 0.17). Similarly, the memantine versus placebo
SMMSE mean score adjusted for baseline favoured memantine at
week 12 [1.4 (95% CI 0.4 to 2.4); p ,0.01] but not at week 6
[1.0(95%CI =20.04 to 2.0)p = 0.06].
Adverse Events
The levels of adverse events were similar for memantine and
placebo (table 3).
Discussion
This is the first completed trial designed primarily to explore the
efficacy of memantine on clinically significant agitation in AD. We
found no significant advantage of memantine versus placebo in the
primary outcome CMAI at week 6 or 12. In addition there were
no significant benefits for memantine in global clinical outcome.
There was a greater improvement in a secondary outcome
measure - the total NPI score for memantine at week 6 and 12.
The post hoc analysis of the NPI agitation/psychosis symptom
cluster also favored memantine at week 6, but not at week12. As
this cluster contained both agitation and psychosis it is not
surprising that the results differ from those for the CMAI. It is
unclear what the clinical meaning of the decrease in the NPI
relative to placebo of 7–10 points is, especially when it is less than
the overall change over time and [31,32], and that, despite the
accompanying cognitive superiority of memantine, it was not
associated with a significant difference in global clinical improve-
ment. As this was a post hoc test, the ‘significance’ of the p value
should be interpreted with caution. This nonetheless merits further
investigation.
This study’s strengths include its relatively broad inclusion
criteria and participants that were generally representative of
people with severe AD with agitation needing clinical interven-
tion in 24-hour care settings in the developed world; in line
with levels in a previous study. [6] Participants had not been
prescribed memantine previously, thus we did not bias the
results by including treatment failures or responders. Nonethe-
less we do not have details of those who were referred but we
were refused permission to assess and this may limit general-
izability. The level of behavioural disturbance on the NPI and
CMAI was higher than in a previous study showing donepezil
was ineffective on the CMAI and NPI [14]. Similarly, previous
retrospective studies suggesting benefits for memantine for
agitation in people with AD have focussed on milder agitation
and over longer periods. It therefore still remains to be
determined whether memantine has a role in the treatment,
prophylaxis or prevention of milder agitation. The changes
reported here contrast to naturalistic studies, where there was
little improvement over time, [12] and suggest that consistent
Figure 2. Mean (+/295% confidence intervals) total CMAI by time and by group. Circles are individual data points; red: memantine, blue:
placebo.
doi:10.1371/journal.pone.0035185.g002
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with findings in other RCTs participation in the study (which
involved substantial researcher input both for participants and
carers) was beneficial in itself.
Limitations of our study include the finding that level of
agitation predicted response both to memantine and to placebo,
which suggests that severe agitation reduces over time, making it
more difficult to establish whether any interventions have a specific
beneficial effect.
Overall our negative findings suggest memantine should not
be routinely used to treat agitation in AD. Most patients in both
groups remained well above the inclusion criteria for significant
agitation after the trial. There was however a benefit for
memantine in overall neuropsychiatric symptoms. In the
absence of sustained or overall clinical benefit this must be
interpreted cautiously. Future studies should test other likely
medications for significant agitation in AD and examine the
Figure 3. Mean (+/295% Confidence intervals) total NPI by time and by group.
doi:10.1371/journal.pone.0035185.g003
Table 3. Adverse events.
Adverse Event Memantine Number (percent) Placebo Number (percent)
Headache 8 (5.9) 6 (4.7)
Fatigue 21 (15.6) 20 (15.6)
Somnolence 37 (27.4) 24 (18.8)
Confusion 23 (17.0) 25 (19.5)
Hallucinations 8 (5.9) 18 (14.1)
Constipation 7 (5.2) 11 (8.6)
Vomiting 5 (3.7) 6 (4.7)
Dizziness 6 (4.4) 1 (0.8)
Abnormal gait 15 (11.1) 10 (7.8)
Seizures 0 0
Death 5 (3.7) 7 (5.5)
doi:10.1371/journal.pone.0035185.t003
Memantine for Agitation in Alzheimer’s Disease
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impact of memantine on a broader cluster of neuropsychiatric
symptoms.
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